Conference Coverage

High-risk patients fared best in lifestyle intervention trial for cognitive decline


 

AT CTAD

References

The program was not associated with any serious adverse events, or any adverse event at all other than musculoskeletal soreness from exercise activities. It also appeared to be practical and made a lasting impact, which was a gratifying finding, Dr. Kivipelto said. At the end of the study, intervention group participants had decreased their body mass index by about 0.8 kg/m2, which was significantly more than for control group subjects. Most reported that they were still eating fish and exercising at least twice a week and eating vegetables every day.

“FINGER is the first long-term trial to show that a multidomain intervention like this one can maintain and improve cognitive decline,” she said. “It important that we’ve also seen the program is feasible, has no obvious side effects, and that it’s not limited to cognitive domains. It also has a positive impact on function and quality of life.”

Dr. Kivipelto had no financial disclosures. The study was supported by grants from the Academy of Finland’s Responding to Public Health Challenges Research Programme, La Carita Foundation, the Alzheimer’s Association, the Alzheimer’s Research and Prevention Foundation, the Juho Vainio Foundation, Novo Nordisk Foundation, the Finnish Social Insurance Institution, the Finnish Ministry of Education and Culture Research, Salama Bint Hamdan Al Nahyan Foundation, the Axa Research Fund, and various University Hospitals in Finland.

*This story was updated on 11/6/2015.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Alzheimer’s patients often had low cerebral amyloid
MDedge Internal Medicine
Physical activity, omega-3 supplements didn’t improve cognitive outcomes
MDedge Internal Medicine
Postop delirium heightens risk of other dangerous complications
MDedge Internal Medicine
Smartphone app can pick up covert hepatic encephalopathy
MDedge Internal Medicine
ESC: Atrial fibrillation accelerates brain atrophy
MDedge Internal Medicine
EASD: High HbA1c linked to elevated dementia risk in patients with 2DM
MDedge Internal Medicine
Prion-like transmission of neurodegenerative pathology stirs concern
MDedge Internal Medicine
Trial to prove utility of amyloid imaging seeks physicians for referrals
MDedge Internal Medicine
ADHD in the elderly: An unexpected diagnosis
MDedge Internal Medicine
Raloxifene ineffective for treating AD patients
MDedge Internal Medicine

Related Articles